

# Thierry Durand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2599486/publications.pdf>

Version: 2024-02-01

22  
papers

1,081  
citations

430874

18  
h-index

677142

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25 years of research in chemistry and biology. <i>Progress in Lipid Research</i> , 2017, 68, 83-108.	11.6	130
2	Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. <i>Neurobiology of Disease</i> , 2014, 68, 66-77.	4.4	118
3	The role of oxidative stress in Rett syndrome: an overview. <i>Annals of the New York Academy of Sciences</i> , 2012, 1259, 121-135.	3.8	95
4	F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. <i>Journal of Lipid Research</i> , 2011, 52, 2287-2297.	4.2	93
5	Partial rescue of Rett syndrome by $\gamma$ -3 polyunsaturated fatty acids (PUFAs) oil. <i>Genes and Nutrition</i> , 2012, 7, 447-458.	2.5	76
6	Isoprostanes and neuroprostanes: Total synthesis, biological activity and biomarkers of oxidative stress in humans. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 107, 95-102.	1.9	72
7	Oxidative stress in Rett syndrome: Natural history, genotype, and variants. <i>Redox Report</i> , 2011, 16, 145-153.	4.5	64
8	Cytokine Dysregulation in <i>MECP2</i> - and <i>CDKL5</i> -Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and $\gamma$ -3 PUFAs. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-18.	4.0	61
9	Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and $\pm$ -linolenic acids; bioactivities and potential use as biomarkers. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 446-455.	2.4	51
10	Redox Imbalance and Morphological Changes in Skin Fibroblasts in Typical Rett Syndrome. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-10.	4.0	44
11	Isoprostanes and 4-Hydroxy-2-nonenal: Markers or Mediators of Disease? Focus on Rett Syndrome as a Model of Autism Spectrum Disorder. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-10.	4.0	36
12	Erythrocyte Shape Abnormalities, Membrane Oxidative Damage, and $\beta$ -Actin Alterations: An Unrecognized Triad in Classical Autism. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	3.0	35
13	Effect of Dietary $\alpha$ -linolenic acid on male reproduction in rabbits. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	4.0	34
14	F2-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. <i>Biochimie</i> , 2013, 95, 86-90.	2.6	30
15	Non-enzymatic cyclic oxygenated metabolites of omega-3 polyunsaturated fatty acid: Bioactive drugs?. <i>Biochimie</i> , 2016, 120, 56-61.	2.6	29
16	Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: Effects of omega-3 polyunsaturated fatty acid supplementation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2014, 91, 183-193.	2.2	25
17	Rett syndrome: An autoimmune disease?. <i>Autoimmunity Reviews</i> , 2016, 15, 411-416.	5.8	25
18	MECP2 Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison with Rett Syndrome. <i>PLoS ONE</i> , 2016, 11, e0150101.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Effects of $\omega$ -3 PUFAs Supplementation on Myocardial Function and Oxidative Stress Markers in Typical Rett Syndrome. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	18
20	Effects of $\omega$ -3 Polyunsaturated Fatty Acids on Plasma Proteome in Rett Syndrome. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	3.0	12
21	Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome. <i>Neuroscience Research</i> , 2016, 105, 28-34.	1.9	7
22	Oxidative stress: a hallmark of Rett syndrome. <i>Future Neurology</i> , 2015, 10, 179-182.	0.5	4